Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Announcement Summary
For personal use only
Entity name
CLARITY PHARMACEUTICALS LTD
Date of this announcement
Wednesday June 01, 2022
The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
Total number of +securities to be issued/transferred
Total number of | |||
ASX +security | +securities to be | ||
code | Security description | issued/transferred | Issue date |
New class - code | Options expiring 26 May 2027 Ex $1.40 | 400,000 | 31/05/2022 |
to be confirmed |
Refer to next page for full details of the announcement
Notification of Issue, Conversion or Payment up of Unquoted | 1 / 7 |
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
CLARITY PHARMACEUTICALS LTD
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
1.2 | Registered number type | Registration number |
ABN | 36143005341 | |
1.3 | ASX issuer code | |
CU6 |
- The announcement is New announcement
- Date of this announcement
1/6/2022
Notification of Issue, Conversion or Payment up of Unquoted | 2 / 7 |
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
For personal use only
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
does not have an existing ASX security code ("new class")
Notification of Issue, Conversion or Payment up of Unquoted | 3 / 7 |
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B
only | ASX +security code | +Security description | ||
New class - code to be confirmed | Options expiring 26 May 2027 Ex $1.40 | |||
+Security type | ISIN code | |||
Options | ||||
use | Date the +securities the subject of this notification were issued | |||
31/5/2022 | ||||
Will all the +securities issued in this class rank equally in all respects from their issue date? | ||||
Yes | ||||
Were any of the +securities issued to +key management personnel (KMP) or an +associate? | ||||
personal | No | |||
Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under | ||||
listing rule 6.1? | ||||
Yes | ||||
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being | ||||
issued. | ||||
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02526829-2A1376557?access_token=8 | ||||
3ff96335c2d45a094df02a206a39ff4 | ||||
Options Details | ||||
+Security currency | Exercise price | Expiry date | ||
AUD - Australian Dollar | AUD 1.40000000 | 26/5/2027 | ||
For | Details of the existing class of +security that will be issued upon exercise or conversion of this new class of | |||
company option | ||||
Other | ||||
Description
Options Expiring 26 May 2027 Ex price $1.40
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02410944-2A1317648?access_token=8 3ff96335c2d45a094df02a206a39ff4
Notification of Issue, Conversion or Payment up of Unquoted | 4 / 7 |
Notification of Issue, Conversion or Payment up of Unquoted Equity Securities
Any other information the entity wishes to provide about the +securities the subject of this notification
Issue details
For personal use only
Number of +securities
400,000
Notification of Issue, Conversion or Payment up of Unquoted | 5 / 7 |
This is an excerpt of the original content. To continue reading it, access the original document here.